TRIPTORELIN (GNRH) - Research Grade Peptide

TRIPTORELIN (GnRH Analogue) – Research-Grade Synthetic Decapeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade, sequence-defined synthetic decapeptide with batch documentation available where supplied
• Defined pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂ molecular structure
• Contains D-tryptophan at position 6, an N-terminal pyroglutamate and a C-terminal glycinamide
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, molecular mass, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Supply may be subject to customer, organisation and intended-use verification
• Handled and supplied exclusively as a research-use laboratory material

Triptorelin is a sequence-defined synthetic decapeptide analogue of gonadotropin-releasing hormone. It is not chemically identical to native GnRH. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage, analytical method development and peptide characterisation. The stated nominal amount refers to the declared triptorelin peptide content of a single vial, subject to the applicable batch documentation and stated assay basis.

Where laboratory dissolution or reconstitution is required, the solvent, buffer, concentration, mixing procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. A universal solvent instruction should not be applied to every triptorelin chemical form, counter-ion presentation or formulated preparation. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: TRIPTORELIN
• Preferred Substance Name: Triptorelin
• Alternative Scientific Names: [D-Trp⁶]-GnRH; [D-Trp⁶]-LHRH; D-Trp⁶ gonadorelin; 6-D-tryptophan luteinising hormone-releasing hormone
• GnRH Relationship: Synthetic decapeptide analogue of gonadotropin-releasing hormone; not chemically identical to native GnRH
• Material Classification: Synthetic sequence-defined modified linear decapeptide
• Sequence Length: Ten amino-acid and modified amino-acid residues
• Complete Modified Peptide Sequence: pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂
• Expanded Sequence: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide
• Systematic Sequence-Based Description: 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide
• Position 6 Modification: D-tryptophan replaces the glycine residue present at position 6 of native GnRH
• N-Terminal Structure: L-pyroglutamate, also described as 5-oxo-L-proline
• C-Terminal Structure: C-terminal glycinamide
• Terminal-Modification Note: The N-terminal pyroglutamyl residue and C-terminal amide form part of the defined triptorelin molecular identity
• Cyclic or Linear Peptide: Linear peptide backbone containing a cyclic pyroglutamyl residue
• Cysteine Content: None
• Disulphide-Bond Content: None; the triptorelin sequence contains no cysteine residues
• Sulphur Content: None; the parent molecular formula contains no sulphur
• Parent Triptorelin CAS Number: 57773-63-4
• Parent Triptorelin PubChem Compound Identifier: CID 25074470
• Parent Triptorelin Unique Ingredient Identifier: 9081Y98W2V
• Parent Triptorelin Molecular Formula: C₆₄H₈₂N₁₈O₁₃
• Parent Triptorelin Average Molecular Weight: Approximately 1311.47 g/mol
• Parent Triptorelin Approximate Monoisotopic Mass: 1310.6309 Da
• Parent-Formula Basis: The molecular formula and molecular weight describe the uncountered parent triptorelin structure containing its N-terminal pyroglutamate, D-tryptophan residue and C-terminal glycinamide
• Triptorelin Acetate CAS Number: 140194-24-7
• Triptorelin Acetate Unique Ingredient Identifier: 43OFW291R9
• Reference Triptorelin Acetate Formula: C₆₄H₈₂N₁₈O₁₃·C₂H₄O₂
• Expanded Triptorelin Acetate Formula: C₆₆H₈₆N₁₈O₁₅
• Reference Triptorelin Acetate Average Molecular Weight: Approximately 1371.52 g/mol
• Acetate-Form Distinction: Triptorelin acetate is a separate supplied salt form and should not be represented using the unqualified molecular formula or molecular weight of the parent peptide
• Reference Triptorelin Pamoate Formula: C₆₄H₈₂N₁₈O₁₃·C₂₃H₁₆O₆
• Expanded Triptorelin Pamoate Formula: C₈₇H₉₈N₁₈O₁₉
• Reference Triptorelin Pamoate Average Molecular Weight: Approximately 1699.9 g/mol
• Pamoate-Form Distinction: Triptorelin pamoate is chemically distinct from both parent triptorelin and triptorelin acetate
• Brand-Name Distinction: Proprietary medicinal brand names should not be used as substitutes for the precise chemical identity of the research material
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion should be stated in the batch Certificate of Analysis
• Purity Interpretation: Chromatographic purity represents the relative chromatographic composition measured under the stated analytical conditions and should not automatically be interpreted as equivalent to total net triptorelin peptide content
• Peptide-Content Specification: Net triptorelin peptide content should be distinguished from chromatographic purity and interpreted alongside counter-ion content, water content, residual solvents and formulation components
• Nominal Amount Basis: The applicable product specification should state whether the declared vial quantity is expressed as parent triptorelin equivalent, total acetate-form material, total pamoate-form material or total formulated lyophilised material
• Sequence Confirmation: The complete ten-residue modified sequence should be confirmed using the applicable supplier, synthesis and batch records
• D-Tryptophan Confirmation: The D configuration of the tryptophan residue at position 6 should be supported by appropriate synthesis records or stereochemical analytical documentation
• N-Terminal Pyroglutamate Confirmation: Molecular-identity documentation should confirm the pyroglutamyl residue and distinguish it from an uncyclised glutamine or glutamic-acid terminal form
• C-Terminal Amidation Confirmation: Molecular-identity documentation should confirm the C-terminal glycinamide and distinguish it from the corresponding free carboxylic acid derivative
• Mass-Spectrometry Confirmation: Molecular identity should be supported by analytical mass data consistent with the exact triptorelin parent or salt form stated for the applicable batch
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied material is parent triptorelin, triptorelin acetate, triptorelin pamoate, a trifluoroacetate-containing form or another salt or counter-ion presentation
• Counter-Ion Specification: Acetate, pamoate, trifluoroacetate or another counter-ion may affect the total supplied material mass, formula weight and calculated net triptorelin content
• Water-Content Specification: Residual water and hydration state may contribute to the total supplied material mass and should be stated or controlled through the applicable batch specification
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, purification, salt conversion, concentration and lyophilisation should be stated or controlled through the batch specification
• Related-Impurity Control: Deletion sequences, truncated peptides, incompletely modified termini, stereochemical impurities, oxidation products and other synthesis-related or process-related substances are separate quality attributes
• Aggregation and Physical State: Aggregation, oligomerisation and other concentration-dependent physical behaviour are separate quality attributes and are not established by a chromatographic purity percentage alone
• Dissolution Method: The appropriate solvent, buffer, concentration and mixing procedure should be selected using the applicable batch documentation and validated laboratory method; a universal bacteriostatic-water instruction should not be applied to every triptorelin chemical form or preparation
• Endotoxin Specification: The applicable bacterial endotoxin or lipopolysaccharide result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Sterility Distinction: A bacterial endotoxin or lipopolysaccharide result does not establish sterility. Sterility should only be claimed where supported by an appropriate validated sterility test and controlled filling process
• Analytical Interpretation: Molecular identity, complete modified sequence, stereochemistry, terminal structure, chromatographic purity, net peptide content, salt form, water content, residual solvents and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for the applicable batch.
✓ Certificate of Analysis – Accessible through the product QR code where a completed batch-specific document has been published.
✓ Safety Data Sheet – Supplied to support appropriate professional laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The complete pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂ structure should be confirmed using the applicable synthesis and batch records.
✓ Stereochemical documentation – The D-tryptophan residue at position 6 should be supported by appropriate synthesis or analytical documentation.
✓ N-terminal modification documentation – The pyroglutamyl residue should be supported by appropriate molecular-identity data.
✓ C-terminal modification documentation – C-terminal glycinamide should be confirmed and distinguished from a free carboxylic acid structure.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified parent or salt-form structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net triptorelin content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – Parent triptorelin, acetate, pamoate, trifluoroacetate-containing material or another salt form should be identified clearly in the applicable product and batch records.
✓ Related-substance documentation – Deletion sequences, stereochemical impurities, terminally modified products and other process-related substances should be controlled as applicable.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or lipopolysaccharide result should identify the analytical method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, terminal modification, purification, salt-form and analytical records are supplied.
✓ Trackable laboratory delivery – Securely packaged and dispatched using transport controls appropriate to the applicable batch stability and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use, pharmacy compounding, self-administration or any form of therapeutic application.

Triptorelin Product Overview

Our research-grade Triptorelin synthetic decapeptide is supplied for controlled analytical method development, peptide identity assessment, high-performance liquid chromatography evaluation, liquid chromatography–mass spectrometry workflows, impurity profiling, reference-material comparison and other verified scientific laboratory investigations.

Triptorelin comprises the defined sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂. The molecule contains an N-terminal pyroglutamyl residue, D-tryptophan at position 6 and a C-terminal glycinamide. These structural features form part of the molecular identity and should be confirmed together with the peptide sequence, stereochemistry and measured molecular mass.

Triptorelin is a modified analogue of gonadotropin-releasing hormone rather than an alternative name for native GnRH. The product title and scientific documentation should therefore use wording such as Triptorelin – GnRH Analogue rather than presenting Triptorelin and GnRH as chemically identical substances.

The CAS number 57773-63-4, molecular formula C₆₄H₈₂N₁₈O₁₃ and average molecular weight of approximately 1311.47 g/mol describe the uncountered parent triptorelin molecule. Where the supplied laboratory material contains acetate, pamoate, trifluoroacetate, residual water, solvents or formulation ingredients, the applicable batch documentation should identify their contribution to the total supplied material mass.

Triptorelin acetate and triptorelin pamoate are distinct supplied chemical forms. Triptorelin acetate has the reference formula C₆₄H₈₂N₁₈O₁₃·C₂H₄O₂ and molecular weight approximately 1371.52 g/mol, while the reference pamoate form has the formula C₆₄H₈₂N₁₈O₁₃·C₂₃H₁₆O₆ and molecular weight approximately 1699.9 g/mol.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, complete amino-acid sequence, D-tryptophan configuration, terminal modifications, chromatographic purity, net peptide content, molecular form, counter-ion content, water content, residual solvents, aggregation, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

Chromatographic purity should not automatically be interpreted as equivalent to total net triptorelin content or proof of correct stereochemistry and terminal modification. Molecular identity should be assessed using the applicable combination of chromatographic, mass-spectrometry, peptide-content and batch-manufacturing documentation.

A bacterial endotoxin or lipopolysaccharide result does not establish sterility, complete molecular identity, correct D-tryptophan configuration, terminal-modification integrity or the absence of every peptide-related and process-related impurity. Any sterility claim must be supported separately by an appropriate validated sterility test and controlled production documentation.

For the majority of routine analytical method development, chromatographic assessment, mass-spectrometry comparison, impurity profiling, peptide-characterisation and general laboratory work, the Regular Triptorelin specification remains highly suitable. The premium black-and-gold ULTIMATE Triptorelin option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin or lipopolysaccharide testing specification for projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet